IDEXX Laboratories Is Defying Global Economic Shocks—How Is It Thriving Amid Tariff Turbulence & Market Volatility?

IDEXX Laboratories reported its first-quarter 2025 financial results, revealing a mixed performance with notable areas of strength as well as challenges. Overall, IDEXX achieved a 5% organic revenue growth, a figure backed by a 4.5% increase in CAG Diagnostics recurring revenues despite facing a 1.5% headwind from fewer equivalent days. The company’s veterinary software and diagnostic imaging revenues were particularly strong, showing a 9% organic gain, highlighting robust demand in this segment.